• 700 Atrium Drive, Suite A, Somerset, NJ 08873
  • (855) 581-9688
  • customerservice@solcohealthcare.com
logo
  • About
  • Products
  • Trade Partner Info
  • Partner with Solco
  • Careers
  • News
  • Contact
  • About
  • Products
  • Trade Partner Info
  • Partner with Solco
  • Careers
  • News
  • Contact

Archives

  • Home
  •  
  • Archives
    • OCTOBER 11, 2022
    • 0 COMMENTS
    SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR NEBIVOLOL TABLETS

    SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR NEBIVOLOL TABLETS

    September 1, 2022 SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR NEBIVOLOL TABLETS SOMERSET, NJ — Solco Healthcare is proud to announce the FDA approval on April 7, 2022 and September 2022 availability of Nebivolol tablets, 2.5mg, 5mg, 10mg and 20mg an AB-rated equivalent to Bystolic® by Allergan, Inc. Nebivolol is a beta-adrenergic blocking agent indicated

    Read more
    • admin
    • 2022,
    • Solco News
    • OCTOBER 11, 2022
    • 0 COMMENTS
    SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR TADALAFIL TABLETS

    SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR TADALAFIL TABLETS

    August 11, 2022 SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR TADALAFIL TABLETS SOMERSET, NJ — Solco Healthcare announces its FDA approval and availability of Tadalafil tablets, 2.5mg, 5mg, 10mg and 20mg, which are AB-rated generics equivalent to Cialis® and Adcirca® by Eli Lily. Tadalafil 2.5mg, 5mg, 10mg and 20mg tablets are indicated for the treatment

    Read more
    • admin
    • 2022,
    • Solco News
    • OCTOBER 11, 2022
    • 0 COMMENTS
    SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR ENALAPRIL MALEATE TABLETS

    SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR ENALAPRIL MALEATE TABLETS

    July 7, 2022 SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR ENALAPRIL MALEATE TABLETS SOMERSET, NJ — Solco Healthcare announces its FDA approval for Enalapril Maleate tablets, 2.5mg, 5mg, 10mg and 20mg which are AB-rated equivalent to Vasotec® by Bausch Health. “This product was developed by our subsidiary – Prinbury Biopharm for Solco. This approval represents

    Read more
    • admin
    • 2022,
    • Solco News
    • NOVEMBER 16, 2021
    • 0 COMMENTS
    THE FDA HAS OFFICIALLY REMOVED ZHEJIANG HUAHAI PHARMACEUTICAL FROM IMPORT ALERT

    THE FDA HAS OFFICIALLY REMOVED ZHEJIANG HUAHAI PHARMACEUTICAL FROM IMPORT ALERT

    THE FDA HAS OFFICIALLY REMOVED ZHEJIANG HUAHAI PHARMACEUTICAL FROM IMPORT ALERT Somerset, NJ, November 15, 2021 – Solco is pleased to announce that the FDA has lifted the ImportAlert (IA) 66-40, “Detention Without Physical Examination of Drugs From Firms Which Have Not MetDrug GMPs”, Published Date: 11/12/2021, from Zhejiang Huahai Pharmaceutical Co. Ltd., at CoastalIndustrial

    Read more
    • admin
    • 2021,
    • Solco News
    • APRIL 17, 2020
    • 0 COMMENTS
    SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR AMPHETAMINE SULFATE Tablets, 5mg and 10mg

    SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR AMPHETAMINE SULFATE Tablets, 5mg and 10mg

    SOMERSET, NJ — Solco Healthcare announces its FDA approval for Amphetamine Sulfate tablets, 5mg and 10mg, which is an AA-rated equivalent to Evekeo® by Arbor Pharmaceuticals. “This approval represents Solco’s first CII product within the ADHD therapeutic treatment. Amphetamine sulfate tablets will be manufactured in our Prinston Laboratories facility located in Charlotte, NC. We are

    Read more
    • admin
    • 2020,
    • Solco News
    • MAY 23, 2019
    • 1 COMMENT
    SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR GLYCOPYRROLATE INJECTION, 0.2 mg/mL

    SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR GLYCOPYRROLATE INJECTION, 0.2 mg/mL

    SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR GLYCOPYRROLATE INJECTION, 0.2 mg/mL CRANBURY, NJ — Solco Healthcare announces its FDA approval for Glycopyrrolate Injection, 0.2mg/mL, which is an AP-rated equivalent to Robinul® by Hikma. “We are very pleased to have received FDA approval for Glycopyrrolate injection.  This approval represents a new chapter for Solco, as we enter

    Read more
    • admin
    • 2019,
    • Solco News
    • JANUARY 18, 2019
    • 0 COMMENTS
    Prinston Pharmaceutical Inc. issues Voluntary Nationwide Recall of Irbesartan and Irbesartan HCTZ Tablets Due to detection of a Trace Amount of Unexpected Impurity, Nnitrosodiethylamine (NDEA) in the Products

    Prinston Pharmaceutical Inc. issues Voluntary Nationwide Recall of Irbesartan and Irbesartan HCTZ Tablets Due to detection of a Trace Amount of Unexpected Impurity, Nnitrosodiethylamine (NDEA) in the Products

    Read PDF here. http://www.solcohealthcare.com/uploads/news/Press-Release-Irbesartan-Recall.pdf

    Read more
    • admin
    • Recall Information
    • DECEMBER 14, 2018
    • 0 COMMENTS
    Press Release – Dec. 14, 2018

    Press Release – Dec. 14, 2018

    FOR IMMEDIATE RELEASE – CRANBURY, NEW JERSEY –  December 14, 2018 On July 12, 2018, Prinston Pharmaceutical Inc. announced that one of its affiliated companies, Solco Healthcare, LLC, based in Cranbury, New Jersey, voluntarily recalled all lots of Valsartan Tablets, 40mg, 160mg, and 320mg; and Valsartan-Hydrochlorothiazide Tablets, 80mg/12.5g, 160mg/25mg, 320mg/12.5mg and 320mg/25mg, to the consumer

    Read more
    • admin
    • Recall Information
    • AUGUST 21, 2018
    • 0 COMMENTS
    Press Release – Update on Valsartan API – A Statement from the Company

    Press Release – Update on Valsartan API – A Statement from the Company

    FOR IMMEDIATE RELEASE – CRANBURY, NEW JERSEY, August 21, 2018. Huahai US Inc., a subsidiary of Zhejiang Huahai Pharmaceutical Co. Ltd is issuing a statement. Recent articles in several print and on-line media have misrepresented information about the discovery of a trace amount of a genotoxic impurity in Valsartan, an active pharmaceutical ingredient (API) made

    Read more
    • admin
    • 2018,
    • Solco News
    • JULY 13, 2018
    • 0 COMMENTS
    Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to detection of a Trace Amount of Unexpected Impurity, N-nitrosodimethylamine (NDMA) in the Products

    Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to detection of a Trace Amount of Unexpected Impurity, N-nitrosodimethylamine (NDMA) in the Products

    Read detail here: http://www.solcohealthcare.com/uploads/news/PressReleaseValsartanRecallFinal.pdf

    Read more
    • admin
    • Recall Information
  • 1
  • 2

Press Release Archives

  • 2016
  • 2017
  • 2018
  • 2019
  • 2020
  • 2021
  • 2022
  • Recall Information
  • Solco News
© 2019 Solco Healthcare. All Rights Reserved.
  • Product Catalog
  • Drug Safety
  • Return Goods Policy